콘텐츠로 건너뛰기
Merck
모든 사진(1)

문서

76884

Supelco

Anthranilamide

matrix substance for MALDI-MS, ≥99.0% (HPLC)

동의어(들):

2-AB, 2-Aminobenzamide, Anthranilic acid amide

로그인조직 및 계약 가격 보기


About This Item

Linear Formula:
2-(H2N)C6H4CONH2
CAS Number:
Molecular Weight:
136.15
Beilstein:
508509
EC Number:
MDL number:
UNSPSC 코드:
12000000
PubChem Substance ID:
NACRES:
NA.21

Grade

matrix substance for MALDI-MS

Quality Level

분석

≥99% (NT)
≥99.0% (HPLC)

형태

crystals

기술

MALDI-MS: suitable

mp

111-113 °C (lit.)

양이온 미량물

Ba: ≤5 mg/kg
Ca: ≤5 mg/kg
Cd: ≤5 mg/kg
Co: ≤5 mg/kg
Cr: ≤5 mg/kg
Cu: ≤5 mg/kg
Fe: ≤30 mg/kg
K: ≤50 mg/kg
Mg: ≤5 mg/kg
Mn: ≤5 mg/kg
Na: ≤150 mg/kg
Ni: ≤5 mg/kg
Pb: ≤5 mg/kg
Zn: ≤5 mg/kg

SMILES string

NC(=O)c1ccccc1N

InChI

1S/C7H8N2O/c8-6-4-2-1-3-5(6)7(9)10/h1-4H,8H2,(H2,9,10)

InChI key

PXBFMLJZNCDSMP-UHFFFAOYSA-N

유사한 제품을 찾으십니까? 방문 제품 비교 안내

애플리케이션

Used for non-selective, efficient fluorescent labeling of glycans. Slightly less sensitive than anthranilic acid (2-AA) for glycan labeling.

분석 메모

metal trace analysis (ICP) corresponds to requirements

관련 제품

제품 번호
설명
가격

픽토그램

Exclamation mark

신호어

Warning

유해 및 위험 성명서

Hazard Classifications

Eye Irrit. 2

Storage Class Code

11 - Combustible Solids

WGK

WGK 1

Flash Point (°F)

>365.0 °F

Flash Point (°C)

> 185 °C


Choose from one of the most recent versions:

시험 성적서(COA)

Lot/Batch Number

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

이 제품을 이미 가지고 계십니까?

문서 라이브러리에서 최근에 구매한 제품에 대한 문서를 찾아보세요.

문서 라이브러리 방문

이미 열람한 고객

Yan Cai et al.
The Analyst, 138(21), 6270-6276 (2013-09-07)
Analysis of oligosaccharides by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS) is often limited by their low ionization efficiency and inadequate fragmentation information. Derivatizations of oligosaccharides to enhance their ionization in MS are widely used, but most of these
Nicholas T Ventham et al.
PloS one, 10(4), e0123028-e0123028 (2015-04-02)
Serum N-glycans have been identified as putative biomarkers for numerous diseases. The impact of different serum sample tubes and processing methods on N-glycan analysis has received relatively little attention. This study aimed to determine the effect of different sample tubes
Antonio da Silva et al.
Leukemia & lymphoma, 55(7), 1609-1617 (2013-09-13)
Biosimilar development involves a target-directed iterative process to ensure a similar product to the originator. Here we report the preclinical development of the proposed biosimilar rituximab (GP2013). Post-translational modifications and bioactivities of GP2013 versus originator rituximab were engineered and monitored
Meritxell Balmaña et al.
Clinica chimica acta; international journal of clinical chemistry, 442, 56-62 (2015-01-18)
Pancreatic adenocarcinoma (PDAC) usually shows an enhanced expression of sialyl-Lewis X (sLe(x)) and related epitopes. PDAC may secrete some of the proteins carrying such increased sLe(x) determinant into serum, so they could be used as PDAC markers. Previously, we identified
Lei Zhu et al.
mAbs, 6(6), 1474-1485 (2014-12-09)
CTLA4-Ig is a highly glycosylated therapeutic fusion protein that contains multiple N- and O-glycosylation sites. Glycosylation plays a vital role in protein solubility, stability, serum half-life, activity, and immunogenicity. For a CTLA4-Ig biosimilar development program, comparative analytical data, especially the

자사의 과학자팀은 생명 과학, 재료 과학, 화학 합성, 크로마토그래피, 분석 및 기타 많은 영역을 포함한 모든 과학 분야에 경험이 있습니다..

고객지원팀으로 연락바랍니다.